<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sotiropoulos, M. G.</style></author><author><style face="normal" font="default" size="100%">Poulogiannopoulou, E.</style></author><author><style face="normal" font="default" size="100%">Delis, F.</style></author><author><style face="normal" font="default" size="100%">Dalla, C</style></author><author><style face="normal" font="default" size="100%">Antoniou, K</style></author><author><style face="normal" font="default" size="100%">Kokras, N</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Innovative screening models for the discovery of new schizophrenia drug therapies: an integrated approach</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Opin Drug Discov</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Antipsychotic Agents/pharmacology/therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">*Psychotic Disorders/drug therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">*Schizophrenia/drug therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">animal models</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">antipsychotics</style></keyword><keyword><style  face="normal" font="default" size="100%">Behavior</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Development</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Schizophrenia</style></keyword><keyword><style  face="normal" font="default" size="100%">Sex differences</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">20210129</style></edition><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">791-806</style></pages><isbn><style face="normal" font="default" size="100%">1746-0441</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Introduction: Schizophrenia is a severe psychiatric disorder affecting millions worldwide. However, available treatment options do not fully address the disease. Whereas current antipsychotics may control psychotic symptoms, they seem notoriously ineffective in improving negative and cognitive symptoms or in preventing functional decline. As the etiology of schizophrenia eludes us, the development of valid animal models for screening new drug targets appears to be a strenuous task.Areas covered: In this review, the authors present the key concepts that validate animal models of schizophrenia, as well as the different screening approaches for novel schizophrenia treatments. The models covered are either based on major neurotransmitter systems or neurodevelopmental, immune, and genetic approaches.Expert opinion: Sadly, due to inertia, research focuses on developing 'anti-psychotics', instead of 'anti-schizophrenia' drugs that would tackle the entire syndrome of schizophrenia. Whereas no perfect model may ever exist, combining different experimental designs may enhance validity, as the over-reliance on a single model is inappropriate. Multi-model approaches incorporating vulnerability, the 'two-hit' hypothesis, and endophenotypes offer a promise for developing new strategies for schizophrenia treatment. Forward and reverse translation between preclinical and clinical research will increase the probability of success and limit failures in drug development.</style></abstract><accession-num><style face="normal" font="default" size="100%">33467920</style></accession-num><notes><style face="normal" font="default" size="100%">10.1080/17460441.2021.1877657</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.First Department of Psychiatry, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</style></auth-address><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record></records></xml>